Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

May 2, 2024

Conditions
COPDRespiratory DiseaseLower Respiratory DiseasePulmonary DiseaseHealthy
Interventions
DRUG

Vapendavir

This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.

Trial Locations (1)

33136

Syneos Health Miami, Miami

Sponsors
All Listed Sponsors
lead

Altesa Biosciences, Inc.

INDUSTRY

NCT05962645 - Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD | Biotech Hunter | Biotech Hunter